MRD in WM: its potential in guiding treatment decisions and as a surrogate endpoint in trials VJHemOnc – Video Journal of Hematology & HemOnc 1:45 2 months ago 61 Далее Скачать
MRD in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisions VJHemOnc – Video Journal of Hematology & HemOnc 2:09 7 months ago 82 Далее Скачать
Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trials VJHemOnc – Video Journal of Hematology & HemOnc 1:18 2 months ago 19 Далее Скачать
Finding the Cure: Exploring the potential of MRD as a novel endpoint J&J Innovative Medicine EMEA 21:18 5 years ago 3 890 Далее Скачать
MRD tests and surrogate endpoint testing HealthTree University for Multiple Myeloma 4:59 1 year ago 139 Далее Скачать
Using MRD as an endpoint in clinical trials VJHemOnc – Video Journal of Hematology & HemOnc 1:38 5 years ago 50 Далее Скачать
MRD as a surrogate endpoint for AML therapy VJHemOnc – Video Journal of Hematology & HemOnc 1:58 4 months ago 115 Далее Скачать
MRD Assessment and Treatment Tailoring J&J Innovative Medicine EMEA 1:28 6 months ago 61 321 Далее Скачать
How does minimal residual disease (MRD) testing affect treatment decisions? International Myeloma Foundation 4:10 6 years ago 1 397 Далее Скачать
MRD as an endpoint in clinical trials VJHemOnc – Video Journal of Hematology & HemOnc 1:31 6 years ago 166 Далее Скачать
The value of MRD as an early endpoint in multiple myeloma clinical trials VJHemOnc – Video Journal of Hematology & HemOnc 1:44 3 months ago 47 Далее Скачать
Using MRD to guide treatment decisions in the clinic VJHemOnc – Video Journal of Hematology & HemOnc 1:27 4 years ago 36 Далее Скачать
Should minimal residual disease (MRD) testing be routinely performed? International Myeloma Foundation 5:05 5 years ago 524 Далее Скачать
Minimal Residual Disease (MRD) Overview | LRF Ed Forum Series Lymphoma Research Foundation 56:04 3 years ago 2 229 Далее Скачать
After ASH 2022, are we closer to using MRD-guided treatment decisions in MM? Multiple Myeloma Hub 7:08 2 years ago 178 Далее Скачать
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1 Duke Margolis 1:01:18 8 years ago 326 Далее Скачать
Opinion: value of MRD as an endpoint in hem-onc clinical trials VJHemOnc – Video Journal of Hematology & HemOnc 2:17 6 years ago 58 Далее Скачать
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 3 Duke Margolis 54:58 8 years ago 204 Далее Скачать
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 2 Duke Margolis 50:13 8 years ago 242 Далее Скачать
